Patent · US Active

CD71 binding fibronectin type III domains

US12037379B2 · kind B2 · utility

0Cited by

58References

20Claims

0Family size

Assignee

ARO Biotherapeutics Company · US

Inventors

Russell C. Addis · Philadelphia, US
Zhanna Druzina · Philadelphia, US
Robert Kolakowski · Philadelphia, US
Steven G. Nadler · Princeton, US
Karyn O'Neil · Spring House, US
Yao Xin · Philadelphia, US

Key dates

Filing date	Apr 14, 2022
Grant date	Jul 16, 2024
Priority date	—
Expiry date	Apr 14, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.